According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Includes thermostabilized Ebola vaccines
Subscribe To Our Newsletter & Stay Updated
